

State of Illinois Drugs and Therapeutics Advisory Board

Minutes for April 11, 2024 Meeting

- I. Dr. Patel opened the meeting at 8:33am.
- II. Roll Call was taken.
- III. No conflicts of interest.
- IV. The January 11, 2024, meeting minutes were unanimously approved.
- V. PDL Drug Appeals

A. Product: Vraylar

Presented by: Neelesh Nadkarni, PharmD, MSPH, Medical Outcomes & Science Liaison

Presented Material Highlights:

- Once daily
- Four indications
- D3 preferring mechanism of action
- Longest half-life of 1 week
- Neutral metabolic profile
- Minimal sedation

Discussion Highlights:

- Well tolerated with coverage of all 4 indications
- We need to expand access to these medications to decrease hospitalizations.
- By the time patients get to a psychiatrist they have likely already tried 1st line drugs
- Commercial insurance companies do make patients fail generics first
- Significant utilization
- Metabolic neutrality plays a role in patients adherence
- Side effect profile in general is a huge determinant in adherence
- Prevention of long-term metabolic issues is important
- Should have metabolic monitoring
- Due to psychiatrist shortages, primary care doctors need a larger tool box
- No studies show superiority to preferred agents

Motion: Dr. Berkowitz moved to make Vraylar preferred.

Second: Dr. Vergara-Rodriguez

Motion passed 7 yes, 1 no, zero abstention.

Role Call:

Albers	yes
Goyal	yes
Moreland	yes
Patel	no

Shaw yes
Vergara-Rodriguez yes
Florence yes
Sproat yes

Motion: Dr. Patel move Vraylar to preferred with PA. (monitoring needed)

Second: Garry Moreland

Motion passed 5 yes, 3 no, 1 abstention

Role /call: Goyal abstain
 Moreland yes
 Albers no
 Patel Yes
 Shaw yes
 Vergara-Rodriguez yes
 Berkowitz no
 Florence no
 Sproat yes

B. Product: Siklos

Presented by: Chris Muollo, Executive Director, Clinical Programs Viking Healthcare

Presented Material Highlights:

- This is a tablet vs a capsule
- Capsules have 26 dosing vs Siklos has 51
- More dosing options for children
- This is a weight based drug

Discussion Highlights:

- Less concern of toxicity
- Manufacturer ask is for preferred in patients 2-17 years old

Motion: Garry Moreland make Siklos preferred with PA

Second: Dr. Berkowitz

Motion passed without dissent.

C. Product: Carbaglu

Presented by: Andrea Hawkinson, Sr. Medical Science Liaison

Presented Material Highlights:

- Request to be at parity to generic product
- Approved for 3 indications vs one
- Recommended in guidelines as 1st line

Discussion Highlights:

- Very low utilization

Motion: Dr. Patel moved to leave Carbaglu as non-preferred

Second: Garry Moreland

Motion passed without dissent

VI. New Drug Appeals

- a. None for this meeting.

VII. Class Reviews

- a. Topic: Adenergetic Combination Inhalers
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Guidelines recommend formoterol for asthma
- Guidelines recommend formoterol for COPD
- Digihalers have shown better compliance
- Trellergy is only triple therapy

Discussion Highlights:

- Discussion around different formulations
- Most patients can use any delivery device if properly trained
- Technique is key to success

Motion: Garry Moreland moved to make Symbicort non-preferred and Breyna preferred

Second: Dr. Patel

Motion passed without dissent.

Motion: Garry Moreland moved to make Advair Diskus non-preferred and Wixela preferred

Second: Dr. Albers

Motion passed without dissent.

Motion: Garry Moreland moved to make Airsupra preferred

Second: Dr. Albers

Motion passed without dissent.

- b. Topic: Anticholinergic Inhalers
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- All approved for COPD
- Spiriva also approved for asthma
- No preference in products in the guidelines

- All well tolerated

Discussion Highlights:

- Nebulized solutions are rarely used
- Spiriva only for pediatrics

Motion: Dr. Vegara-Rodriguez moved to leave class as is

Second: Dr. Albers

Motion passed without dissent.

- c. Topic: Beta Adrenergic Inhalers
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Albuterol inhalers are available for 2 years and older
- Make terbutaline tablets non-preferred
- Digihalers are sometimes better for some patients

Discussion Highlights:

- Powders are sometimes needed

Motion: Dr. Vegara-Rodriguez moved to make ProAir Digihaler preferred

Second: Dr. Albers

Motion passed without dissent

Motion: Garry Moreland moved to make terbutaline tablets non-preferred

Second: Dr. Patel

Motion passed without dissent

- d. Topic: Steroid Inhalers
Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Consider age range for devices
- Differing delivery methods are also available
- Fluticasone Aerosol and Asmanex HFA are once daily all others are twice daily
- Arnuity adds a second fluticasone option and is once daily
- Lots of utilization of QVAR

Discussion Highlights:

- Make Arnuity preferred
- Generic fluticasone powder preferred

Motion: Garry Moreland moved to make Arnuity preferred

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

Motion: Garry Moreland moved to make Fluticasone powder preferred

Second: Dr. Albers

Motion passed without dissent

Motion: Dr. Vergara-Rodriguez moved to make Pulmicort preferred

Second: Dr. Albers

Motion passed without dissent

VIII. New Drug Initial Reviews

A. Product: Daybue

- Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- For Rett's Syndrome
- Severe and rare neurodevelopment syndrome
- Loss of hand and fine motor symptoms
- Approved for 2 years and above
- Diarrhea in 80.6% was main side effect
- Guidelines do not mention since this was recently approved
- Only drug for core symptoms of Rett's

Discussion Highlights:

- Very low evidence of efficacy with high incidence of side effects
- 60% in study had no response
- Reviewing on a case by case basis
- Not enough clinical evidence at this time to fully back this as preferred

Motion: Dr. Patel moved to leave non-preferred

Second: Dr. Vergara-Rodriguez

Motion passed without dissent.

B. Product: Skyclarys

Presented by: Jen Phillips, PharmD/Daphne Ni, Medical Account Director

Presented Material Highlights:

- For Friedrich's Ataxia
- Symptoms range from mild to severe
- Hallmark symptom is loss of motor function
- Most require wheelchair 15 years after diagnosis
- Oral
- Some baseline labs should be run
- 2 point increase in MFARS score was seen
- No published US guidelines

Discussion Highlights:

- Increase of 2 points out of 93 does not seem hugely significant
- Only product for this disease
- Decrease in falls was seen
- Continue to watch long-term results
- Substantial metabolic side effects

Motion: Dr. Vergara-Rodriguez moved to leave non-preferred

Second: Dr. Patel

Motion passed with no dissent.

C. Product: Xdemvy

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- For demodex blephoritis
- Mites on the eyelashes
- Eye drops
- Side effects were burning on administration
- Resistance to other treatments is beginning to be seen
- Highly effective

Discussion Highlights:

- Most patients are mild to moderate and respond to other treatments
- Only ophthalmic administration
- PA criteria is not stringent

Motion: Garry Moreland moved to leave non-preferred

Second: Dr. Berkowitz

Motion passed with no dissent.

IX. Public Testimony

Speaker	Product	Organization
Neelesh Nadkarni, PharmD, MSPH, Medical Outcomes & Science Liaison	Vraylar	AbbVie
Chris Muollo, Executive Director, Clinical Programs	Siklos	Viking Healthcare on behalf of Medunik USA
Andrea Hawkinson, Sr. Medical Science Liaison	Carbaglu	Recordati Rare Diseases, Inc.
Stacey Repotski, PharmD, HEOR Director	Daybue	Acadia Pharmaceuticals
Daphne Ni, Medical Account Director	Skyclarys	Biogen
Judy Kelloway, Pharm D Dir, Field Medical Lead	Trellegy Ellipta	GSK
Jalal Damani, DO	Trelegy Ellipta	Swedish Hospital-Endeavor Health/Northshore
Rajive Tandon, MD	Trellegy Ellipta	GSK
Amy Kreher, Caregiver	Daybue	

Robin Ryther, MD, PhD Director, Rett Spectrum Clinic, Associate Prof of Neurology, Washington University of Medicine	Daybue	Rett Spectrum Clinic, Associate Prof of Neurology, Washington University of Medicine
Becky Young, Parent Advocate	Skyclarys	
Emily Young, MSW	Skyclarys	

- X. Provider Review Request
 - None at this meeting.
- XI. Future Agenda Preview
 - August 1, 2024
 - October 10, 2024
- XII. HFS Update
 - None due to time constraint
- XIII. Department Update-Jose Jimenez
- XIV. Adjournment-Dr. Patel adjured the meeting at 11:27 am.

Attendees

The names of board members and speakers are bolded.

Panelist List

1. Alyssa Stephenson
2. Sheri Dolan
3. **Arvind Goyal**
4. Heather Freeman
5. **Paul Berkowitz**
6. **Janet Albers**
7. Jennifer Dewitt
8. Jose Jimenez
9. **Garry Moreland**
10. Claudia Colombo
11. **Maurice Shaw**
12. **Nicole Florence**

13. **Pamela Vergara-Rodriguez**
14. Mary Moody
15. **Mahesh Patel**
16. Melissa Davis
17. **Steve Sproat**
18. Thomas Dorn
19. Jen Phillips

Attendee List

1. A Meizlik
2. Amy Breen
3. **Amy Kreher**
4. **Andrea Hawkinson**
5. **Becky Young**
6. Bethany Howell
7. Brianna Hudak
8. Brittany Jacoby
9. Oliva Capperella
10. Chase Williams
11. **Chris Muollo**
12. Clemice Hurst
13. Dami Adeyemi
14. Dami HCSC
15. **Daphne Ni**
16. **Emily Young**
17. Doug Johnson
18. Gary Parenteau
19. Gregg Stein
20. Huzefa Master – Meridian

21. Jamie Dean
22. Janie Huff
23. Jim Sharp
- 24. Judy Kelloway**
25. Keith O'Hara
26. Kelly Hamilton
27. Kelly Petrowski
28. Kellyn Madden
29. Kenneth Ring
30. Kevin Hall – Sanofi
31. Kimberly Canfield
32. Madison Zeltwanger-Artia Solutions
33. Mariah J Scott
34. Marissa
35. Mark Baldrige
36. Mary Kaneaster
37. Matt J
38. Melissa Davis
39. Michele Shirley - Indivior
- 40. Neelesh Nadkarni**
41. Nichole Palusinski
42. Ravi Patel
43. Renetta Mosley
- 44. Robin Ryther**
45. Rod Scott
46. Ron Abraham
47. Ryan Segroves
48. Samantha
49. Shankari Sureshababu

50. **Stacey Repotski**
51. Steve Patterson
52. Sunny Hirpara
53. Tamburo Jennifer
54. Thomas Vayalil
55. Tyler Craddock – Bluebid Bio